Decreased serum levels of glial markers and their relation with clinical parameters in patients with schizophrenia

Basit Öğe Kaydı
dc.contributor.authorCetin, Ihsan
dc.contributor.authorDemirel, Omer Faruk
dc.contributor.authorSaglam, Tarik
dc.contributor.authorYildiz, Nazim
dc.contributor.authorDuran, Alaattin
dc.date.accessioned2025-03-26T17:34:43Z
dc.date.available2025-03-26T17:34:43Z
dc.date.issued2023
dc.departmentİstanbul Esenyurt Üniversitesi
dc.description.abstractObjective: The neurodevelopmental hypothesis of schizophrenia suggests that alterations of glial fibrillary acidic protein (GFAP) and glial cell line-derived neurotrophic factor (GDNF) functions may play a role in the pathogenesis of schizophrenia. However, there is limited information about the relationship of these molecules with the clinical features of schizophrenia. In this study, it was aimed to compare patients with schizophrenia and healthy controls in terms of serum GFAP and GDNF levels and to investigate the effects of clinical parameters on serum levels of molecules in patients with schizophrenia. Method: 37 patients with schizophrenia followed in the psychosis unit and 37 age- and sex-matched healthy controls without a history of psychiatric disease were recruited in study. The patients evaluated through the Turkish version of positive and negative syndrome scale. On the other hand, sociodemographic question form was applied to both the patients and the healthy controls. Results: Serum GDNF and GFAP levels of patients with schizophrenia were significantly lower than those of healthy controls. Furthermore, serum GDNF levels were negatively correlated with general and negative syndrome scales (PANSS) in these patients. Conclusion: It has been observed that there is a relationship between PANSS and changes in the GDNF levels of schizophrenia patients. However, larger clinical studies in which these markers are also measured in cerebrospinal fluid are needed to understand the biological mechanisms underlying these associations and to understand whether glial markers could be useful as biomarkers for the diagnosis of schizophrenia.
dc.description.sponsorshipscientific research project unit of Batman University [BTUBAP-2016-SYO-1]
dc.description.sponsorshipThis research was supported by the scientific research project unit of Batman University (Project Number: BTUBAP-2016-SYO-1).
dc.identifier.doi10.5505/kpd.2023.81557
dc.identifier.endpage162
dc.identifier.issn1302-0099
dc.identifier.issn2146-7153
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85173128410
dc.identifier.scopusqualityQ4
dc.identifier.startpage155
dc.identifier.trdizinid1257308
dc.identifier.urihttps://doi.org/10.5505/kpd.2023.81557
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1257308
dc.identifier.urihttps://hdl.handle.net/20.500.14704/842
dc.identifier.volume26
dc.identifier.wosWOS:001094376800002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherKlinik Psikiyatri Dergisi
dc.relation.ispartofKlinik Psikiyatri Dergisi-Turkish Journal of Clinical Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250326
dc.subjectSchizophrenia; Neurodegeneration; GFAP; GDNF; Glial Markers; PANSS Scores
dc.titleDecreased serum levels of glial markers and their relation with clinical parameters in patients with schizophrenia
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Sanat ve Sosyal Bilimler Fakültesi Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu